Contribution of central 5-HT2 receptors in the occurrence of locomotor activity and myoclonia in freely moving rats exposed to high pressure

NeuroReport

Volumn 7, Issue 15-17, 1996, Pages 2687-2690

  Kriem, Badreddine ^a   Rostain, Jean Claude ^a   Abraini, Jacques H ^b  

^a CNRS   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

5 HT2 receptors; HPNS; Ketanserin; Locomotor activity; m CPP; Myoclonia; Pressure; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; KETANSERIN; RECEPTOR SUBTYPE; SEROTONIN 2 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HIGH PRESSURE NEUROLOGICAL SYNDROME; LOCOMOTION; MALE; MYOCLONUS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029832345     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199611040-00056     Document Type: Article

References (26)

1. Halsey MJ. Physiol Rev 62, 1341-1377 (1982).
2. Bennett PB and Rostain J-C. The high pressure nervous syndrome. In: Bennett PB and Elliott DH, eds. The Physiology and Medicine of Diving. London: Saunders, 1993: 194-237.
3. Abraini JH and Fechtali T. Neurosci Biobehav Rev 16, 597-602 (1992).
4. Wardley-Smith B, Hudson S, Dore CJ et al. Undersea Biomed Res 17, 275-286 (1990).
5. Kriem B, Rostain J-C and Abraini JH, Neurosci Lett 196, 1-4 (1995).
6. Kriem B, Abraini JH and Rostain J-C. Pharmacol Biochem Behav 53, 257-264 (1996).
7. Koenig JFR and Klippel RA. The Rat Brain: a Stereotaxic Atlas. New York: Krieger, 1967.
8. Tomei C, Abraini JH and Rostain J-C. Physiol Behav 49, 393-396 (1991).
9. Hoyer D, Clarke DE, Fozard JR et al. Pharmacol Rev 46, 157-203 (1994).
10. Bradley PB, Engel G, Feniuk W et al. Neuropharmacology 25, 563-576 (1986).
11. Kriem B, Rostain J-C and Abraini JH. Involvement of 5-HT receptors in the pressure-induced disorders in DA transmission in freely-moving rats. In: Rostain J-C, Macdonald AG, Marquis RE, eds. Basic and Applied High pressure Biology IV. Marseille: Medsubhyp, 1995: 31-36.
12. Abraini JH, Rostain J-C. J Appl Physiol 71, 638-643 (1991).
13. Pratt GD, Bowery NG, Kilpatrick GJ et al. Trends Pharmacol Sci 11, 135-137 (1990).
14. Davies MF, Deisz RA, Prince DA et al. Brain Res 423, 347-352 (1987).
15. Curzon G and Kennett GA. Trends Pharmacol Sci 11, 181-182 (1990).
16. Lucki I, Ward HR, Frazer A. J Pharmacol Exp Ther 249, 155-164 (1989).
17. Pazos A and Palacios JM. Brain Res 346, 205-230 (1985).
18. Weissenborn R and Winn P. Behav Brain Res 51, 127-137 (1992).
19. Abraini JH, Fechtali T and Rostain J-C. Neuroscience 50, 395-402 (1992).
20. Leysen J, Awouters F, Kennis L et al. Life Sci 28, 1015-1022 (1981).
21. 2 receptors. In: Saxena PR, Wallis DI, Wouders W et al. eds. Cardiovascular Pharmacology of 5-Hydroxytryptamine. Dordrecht: Kluwer, 1990: 81-100.
22. Tricklebank MD. Behavioural actions of 5-HT. In: Rand MJ and Raper C, eds. Pharmacology: Proceeding of the 10th International Conference of Pharmacology. Amsterdam: Excerpta Medica. 1987: 299-302.
23. Lucki I. Neurosci Biobehav Rev 16, 83-93 (1992).
24. Benloucif S, Keegan MJ and Galloway MP. J Pharmacol Exp Ther 265, 373-377 (1993).
25. Galloway MP, Suchowski CS, Keegan MJ et al. Synapse 15, 90-92 (1993).
26. Pessia M, Jiang ZG, North RA et al. Brain Res 654, 324-330 (1994).